Question

The main point of this evidence is that high frequencies of gene editing with CRISPR were observed in CD34+ HSPCs from healthy donors, leading to an increase in fetal hemoglobin levels in edited cells. This gene editing approach is used to potentially treat or improve disorders related to abnormal hemoglobin production, such as sickle cell disease or beta thalassemia.

so in this casse the crisprs cas9 is only being used right

Answer 1

[AI-generated answer — Bot GPT 3.5]

Yes, in this case, CRISPR-Cas9 technology is being used specifically for gene editing in CD34+ hematopoietic stem and progenitor cells (HSPCs) to increase fetal hemoglobin levels. This approach has the potential to treat or improve disorders related to abnormal hemoglobin production, such as sickle cell disease or beta thalassemia.